

New Year, New Capabilities for Avéma Pharma Solutions



Avéma Pharma Solutions (Booth #1034 at CPhI NA), a leading contract and development manufacturing organization (CDMO), has made significant investments to enable new capabilities and expand its service offerings going into 2023. The company recently added 135,000 sq. ft to their footprint in southern Florida, is building an expanded and an upgraded research and development (R&D) center, has added two new Korsch presses and installed a high-speed bottling line, all in Miami. In addition, Avéma and its parent company, PL Developments, has purchased a CFR 211 and CFR 111- compliant facility in New York that manufactures gummies and gums.

“Avéma is committed to investing in the infrastructure that will enable our customers to develop new products and explore innovative delivery systems,” said Jeff Speicher, Commercial General Manager. “We continually upgrade our equipment so that we can provide our customers with the highest quality products and extend our capabilities. For example, the new Korsch presses have extremely tight tolerances and have the flexibility to be used for a variety of tablet forms

including Multi-unit Pellet System (MUPS) Wuster coated beads, as well as bilevel and trilevel capabilities.”

Speicher went on to explain that the company’s investment in gummies is in response to an industry-wide interest in finding delivery systems for Rx and OTC products that will help overcome reluctance to take oral liquid or solid dose drugs. “Gummies have the potential to increase compliance and we have the capabilities to formulate great tasting functional gummies.” Leading the gummy initiative is Mitchell Slade, who recently joined Avéma as President, Avéma Gummy Solutions and Chief Operating Officer for PL Developments. Slade spent more than 20 years at Nature’s Bounty (now The Bountiful Company) where he led new product development, commercializing over 1,000 products.

The investments made by Avéma demonstrate the company’s dedication to their mission of providing a full-service CDMO experience to their customers from concept to commercialization customers at every stage of their product’s life cycle, including product development, method development and validation, FDA approvals, pilot manufacturing, tech transfer and commercial scale up, all under the same roof and with the oversight of a single portfolio manager.

[Avéma Pharma Solutions](#) is a division of [PL Developments](#), a leading manufacturer, packager, and distributor of over-the-counter (OTC) pharmaceutical products and consumer healthcare goods. PL Developments works in harmony with Avéma Pharma Solutions to deliver a unique offering that combines true full turnkey product development with manufacturing capabilities. With 11 sites throughout North America, including our full-service Rx Miami facilities, we offer the breadth of experience of almost 40 years of product development, manufacturing, experience in product scale up and regulatory submissions. We have the capabilities to handle your drug outsourcing needs either big or small.

Avéma Pharma Solutions
a Division of PL Developments
www.avemapharma.com
jspeicher@avemapharma.com
© Avéma Pharma Solutions 2023

